Effects of allogeneic blood transfusion in patients with stage ii colon cancer

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 1, 2013, Pages 347-350

  Meng, Jin ^a   Lu, Xiao Bo ^a   Tang, Yuan Xin ^a   Sun, Gong Ping ^a   Li, Xin ^a   Yan, Yi Fei ^a   Liang, Gao Feng ^a   Ma, Si Ping ^b   Li, Xiao Xia ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b LIAONING CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Blood transfusion; Colon cancer; Distant metastasis; Local recurrence

Indexed keywords

EID: 84877110588     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.1.347     Document Type: Article

References (20)

1. Aghili M Izadi S, Madani H, et al (2010). Clinical and pathological evaluation of patients with early and late recurrence of colorectal cancer. Asia Pac J Clin Oncol, 6, 35-41.
2. Amato A, Pescatori M (2006). Perioperative blood transfusions for the recurrence of colorectal cancer. Cochrane Database Syst Rev, 25, CD005033.
3. Bordin JO, Chiba AK, Carvalho KI, et al (1999). The effect of unmodified or prestorage white cell-reduced allogeneic red cell transfusions on the immune responsiveness in orthopedic surgery patients. Transfusion, 39, 718-23.
4. Busch OR, Hop WC, Marquet RL, et al (1994). Blood transfusions and local tumor recurrence in colorectal cancer. Evidence of a noncausal relationship. Ann Surg, 220, 791-7.
5. Center MM, Jemal A, Smith RA, et al (2009). Worldwide variations in colorectal cancer. CA Cancer J Clin, 59, 366-78.
6. Chung M, Steinmetz OK, Gordon PH (1993). Perioperative blood transfusion and outcome after resection for colorectal carcinoma. Br J Surg, 80, 427-32.
7. Compton CC, Fielding LP, Burgart LJ, et al (2000). Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med, 124, 979-94.
8. Gantt CL (1981). Red blood cells for cancer patients. Lancet, 12, 363.
9. Gascón P, Zoumbos NC, Young NS (1984). Immunologic abnormalities in patients receiving multiple blood transfusions. Ann Intern Med, 100, 173-7.
10. Ghio M, Contini P, Mazzei C, et al (1999). Soluble HLA class I, HLA class II, and Fas ligand in blood components: a possible key to explain the immunomodulatory effects of allogeneic blood transfusions. Blood, 93, 1770-7.
11. Ikuta S, Miki C, Hatada T, et al (2003). Allogenic blood transfusion is an independent risk factor for infective complications after less invasive gastrointestinal surgery. Am J Surg, 185, 188-93.
12. Kaplan J, Sarnaik S, Gitlin J, et al (1984). Diminished helper/ suppressor lymphocyte ratios and natural killer activity in recipients of repeated blood transfusions. Blood, 64, 308-10.
13. Kobayashi H, Mochizuki H, Sugihara K, et al (2007). Characteristics of recurrence and surveillance tools after curative resection for colorectal cancer: a multicenter study. Surgery, 14, 167-75.
14. Peters WR, Fry RD, Fleshman JW, et al (1989). Multiple blood transfusions reduce the recurrence rate of Crohn's disease. Dis Colon Rectum, 32, 749-53.
15. Vamvakas EC (1995). Perioperative blood transfusion and cancer recurrence: meta-analysis for explanation. Transfusion, 35, 760-8.
16. van der Voort van Zijp J, Hoekstra HJ, Basson MD (2008). Evolving management of colorectal cancer. World J Gastroenterol, 14, 3956-67.
17. Voogt PJ, van de Velde CJ, Brand A, et al (1987). Perioperative blood transfusion and cancer prognosis. Different effects of blood transfusion on prognosis of colon and breast cancer patients. Cancer, 59, 836-43.
18. Weiden PL, Bean MA, Schultz P (1987). Perioperative blood transfusion does not increase the risk of colorectal cancer recurrence. Cancer, 60, 870-4.
19. Ydy LR, Slhessarenko N, de Aguilar-Nascimento JE (2007). Effect of perioperative allogeneic red blood cell transfusion on the immune -inflammatory response after colorectal cancer resection. World J Surg, 31, 2044-51.
20. Zdravkovic D, Bilanovic D, Randjelovic T, et al (2011). Allogeneic blood transfusion in patients in Dukes B stage of colorectal cancer. Med Oncol, 28, 170-4.